Gerald Baker Financial Group LLC Takes $1.55 Million Position in Merck & Co., Inc. $MRK

Key Points

• Gerald Baker Financial Group LLC opened a new position in Merck & Co. during the first quarter, buying 12,878 shares valued at about $1.55 million.
• Several analysts turned more positive on Merck, with firms like Wells Fargo, JPMorgan, and Bank of America raising price targets and assigning overweight/buy ratings. MarketBeat data shows a consensus rating of Moderate Buy with a $133.94 target.
• Merck’s shares rose 3.3% as news highlighted FDA approval of Lipfendra, a first-of-its-kind once-daily oral PCSK9 inhibitor that could become a new growth driver for the company.

Gerald Baker Financial Group LLC acquired a new position in Merck & Co., Inc. (NYSE:MRK - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 12,878 shares of the company's stock, valued at approximately $1,549,000.

Several other institutional investors have also recently made changes to their positions in the business. Kingdom Financial Group LLC. purchased a new position in Merck & Co., Inc. in the 4th quarter worth approximately $25,000. Abound Financial LLC purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at approximately $26,000. Prosperity Bancshares Inc purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at approximately $26,000. High Note Wealth LLC raised its position in shares of Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company's stock valued at $31,000 after buying an additional 109 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $31,000. Hedge funds and other institutional investors own 76.07% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on MRK. Wells Fargo & Company upped their target price on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 8th. JPMorgan Chase & Co. lifted their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an "overweight" rating in a report on Monday. Bank of America boosted their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a "buy" rating in a research note on Tuesday, June 30th. CICC Research assumed coverage on shares of Merck & Co., Inc. in a report on Wednesday, June 24th. They set an "outperform" rating and a $138.00 price objective for the company. Finally, Citigroup initiated coverage on Merck & Co., Inc. in a research report on Wednesday, May 6th. They set a "neutral" rating and a $125.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $133.94.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: FDA approval of Lipfendra creates a new commercial growth driver and strengthens Merck’s long-term pipeline diversification. Merck's cholesterol pill gets US FDA approval
• Positive Sentiment: Lipfendra is the first and only once-daily oral PCSK9 inhibitor approved by the FDA, which could give Merck a first-mover advantage in a large cholesterol market. Merck's LIPFENDRA approval release
• Neutral Sentiment: Analysts are lifting price targets and fair value estimates, reflecting improved sentiment around Merck’s pipeline and earnings outlook. Merck Snags A First-Of-Its-Kind Approval, And Shares Jump
• Neutral Sentiment: Merck also reported additional positive clinical and regulatory updates for Keytruda and its HIV pipeline, which support the broader investment case but are less immediate than the Lipfendra approval. Merck's HIV Pipeline Nears Key Inflection Point

Merck & Co., Inc. Trading Up 3.3%

MRK opened at $127.67 on Friday. The firm has a market cap of $315.32 billion, a P/E ratio of 35.96, a P/E/G ratio of 4.26 and a beta of 0.19. Merck & Co., Inc. has a 12 month low of $76.66 and a 12 month high of $130.29. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The stock has a 50-day moving average of $119.79 and a 200 day moving average of $116.86.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company had revenue of $16.29 billion for the quarter, compared to analysts' expectations of $15.85 billion. During the same period in the previous year, the firm posted $2.22 earnings per share. The firm's revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, research analysts forecast that Merck & Co., Inc. will post 3.17 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th were given a dividend of $0.85 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.7%. Merck & Co., Inc.'s payout ratio is currently 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.